Development, Statistical Optimization and Characterization of Fluvastatin Loaded Solid Lipid Nanoparticles: A 3<sup>2</sup> Factorial Design Approach
The purpose of the present research work was to design, optimize, and evaluate fluvastatin-loaded solid lipid nanoparticles (FLV-SLNPs) using 3<sup>2</sup> factorial design for enhancing the bioavailability. Fluvastatin has several disadvantages, including the low solubility and substant...
Main Authors: | Afzal Haq Asif, Prasanna Kumar Desu, Rajasekhar Reddy Alavala, Gudhanti Siva Naga Koteswara Rao, Nagaraja Sreeharsha, Girish Meravanige |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/3/584 |
Similar Items
-
A COMPARISON BETWEEN FLUVASTATIN AND LOVASTATIN EFFECTS IN IRANIAN PATIENTS WITH HYPERCHOLESTEROLEMIA
by: S. Moradm, et al.
Published: (1998-08-01) -
A COMPARISON BETWEEN FLUVASTATIN AND LOVASTATIN EFFECTS IN IRANIAN PATIENTS WITH HYPERCHOLESTEROLEMIA
by: S. Moradm, et al.
Published: (1998-12-01) -
Glutamate-Evoked Ca<sup>2+</sup> Responses in the Rat Suprachiasmatic Nucleus: Involvement of Na<sup>+</sup>/K<sup>+</sup>-ATPase and Na<sup>+</sup>/Ca<sup>2+</sup>-Exchanger
by: Pi-Cheng Cheng, et al.
Published: (2023-03-01) -
Heterotridentate Organomonophosphines in Pt(κ<sup>3</sup>–X<sup>1</sup>P<sup>1</sup>X<sup>2</sup>)(Y) (X<sup>1,2</sup> = N<sup>1,2</sup> or S<sup>1,2</sup>), Pt(κ<sup>3</sup>–P<sup>1</sup>N<sup>1</sup>X<sup>1</sup>)(Y) (X<sup>1</sup> = O, C, S or Se) Pt(κ<sup>3</sup>–P<sup>1</sup>S<sup>1</sup>Cl<sup>1</sup>)(Cl) and Pt(κ<sup>3</sup>–P<sup>1</sup>Si<sup>1</sup>N<sup>1</sup>)(OL)—Structural Aspects
by: Milan Melník, et al.
Published: (2022-12-01) -
Na<sup>+</sup>,K<sup>+</sup>-ATPase with Disrupted Na<sup>+</sup> Binding Sites I and III Binds Na<sup>+</sup> with Increased Affinity at Site II and Undergoes Na<sup>+</sup>-Activated Phosphorylation with ATP
by: Hang N. Nielsen, et al.
Published: (2024-01-01)